Bladder cancer trial halted: could trilaciclib have saved bone marrow?
Disease control
Terminated
This phase 2 trial tested whether adding trilaciclib (Cosela) to standard chemotherapy and avelumab could help people with advanced bladder cancer by protecting their bone marrow. The study enrolled 92 adults with untreated, locally advanced or metastatic urothelial carcinoma. Un…
Phase: PHASE2 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:04 UTC